<DOC>
	<DOCNO>NCT01784666</DOCNO>
	<brief_summary>This study investigate medication isradipine , currently approve FDA treat high blood pressure , treatment depression bipolar disorder . Isradipine placebo ( contains active medication ) use `` add-on '' lithium , valproate , and/or atypical antipsychotic individual currently experience major depressive episode . Our hypothesis isradipine superior placebo improve depressive symptom .</brief_summary>
	<brief_title>Adjunctive Isradipine Treatment Bipolar Depression</brief_title>
	<detailed_description>Primary Aim : To estimate antidepressant efficacy isradipine versus placebo adjunct lithium , valproate , and/or atypical antipsychotic among individual bipolar I disorder nonpsychotic major depressive episode . Hypothesis : Isradipine superior placebo improvement depressive symptom assess Montgomery-Asberg Depression Rating Scale ( MADRS ) .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Isradipine</mesh_term>
	<criteria>Age 1865 write informed consent meet DSMIV criterion ( SCIDI/P ) bipolar I disorder , current episode depress MADRS score least 20 ( i.e. , moderate depression ) great 34 ( i.e. , severe depression ) screen baseline visit YMRS score &lt; 12 screen baseline visit currently treat lithium preparation ( carbonate citrate ) stable dose least 4 wks level &gt; 0.6 &lt; 1.0 ; and/or valproate stable dose least 4 wks level &gt; 60 &lt; 110 ; and/or atypical antipsychotic stable dose least 4 week ( least minimum FDAlabeled dose ) Caucasian selfreport please see discussion Psychotic feature current episode , assess YMRS item # 8 &gt; 6 [ treatment guideline urge use antipsychotic may confound isradipine result ] felt study clinician require inpatient hospitalization adequate management ( include serious suicide homicide risk , assess evaluate clinician ) 3 fail pharmacologic intervention current major depressive episode , exclude lithium/valproate/other atypical antipsychotic [ response rate subject likely extremely low would require substantially largerscale study identify treatment effect ] obsessivecompulsive disorder , diagnosis DSMIV anxiety disorder anxiety disorder bipolar disorder primary focus clinical attention current substance use disorder nicotine , SCIDI/P primary clinical diagnosis personality disorder , comorbid diagnosis antisocial borderline personality disorder pregnant woman woman child bear potential use medically accept mean contraception ( include oral contraceptive implant , condom , diaphragm , spermicide , intrauterine device , tubal ligation , partner vasectomy ) woman breastfeed unstable medical illness include cardiovascular , hepatic , renal , respiratory , endocrine , neurological , hematological disease , base review medical history , physical examination , screen laboratory test ( include clinical laboratory evidence hypothyroidism ; maintain thyroid medication must euthyroid least 1 month Visit 1 ) history hypertension current treatment hypertension current use isradipine history anaphylactic reaction intolerance isradipine component preparation ECG abnormalities entry : prolonged QTc complete incomplete bundle branch block patient take investigational psychotropic drug within last 3 month patient receive excluded antipsychotic antidepressant within 2 week prior study entry patient require continued treatment exclude medication ( see ) . Excluded medication : antidepressant , antipsychotic , anticonvulsant ( valproate ) , could influence calcium signal impact mood ; calcium channel blocker ; antihypertensive risk cause hypotension ; drug know interact isradipine . Benzodiazepines sedativehypnotic agent ( e.g. , zolpidem ) may initiate study entry ; subject require agent remove study . Allowed : Sedativehypnotic agent dosage stable 4 week prior study entry ; thyroid estrogen replacement provide dosage stable 3 month . Acceptable anticonvulsant include lamotrigine , valproate , gabapentin , topiramate , oxcarbazepine , carbamazepine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Depression</keyword>
	<keyword>Lithium</keyword>
	<keyword>Valproate</keyword>
	<keyword>Isradipine</keyword>
</DOC>